Patents Examined by Nancy Vogel
  • Patent number: 8349555
    Abstract: The emerging concept of cancer stem cells suggests that activation in transformed cells of “stemness” genetic pathways (e.g., normal stem cells' self-renewal pathways) may contribute to the survival life cycle of cancer stem cells, and to tumor progression and metastasis of the malignancy. Thus, activation of “stemness” genes in cancer cells may be associated with aggressive clinical behavior and increased likelihood of therapy failure. General methods and kits associated with prediction of clinical outcome for a disease state of a subject based on gene expression analysis are described. The invention includes determining expression of at least three genes selected from the group consisting of GBX2, MKI67, CCNB1, BUB1, KNTC2, USP22, HCFC1, RNF2, ANK3, FGFR2, and CES1, and mouse homologs thereof.
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: January 8, 2013
    Inventor: Gennadi V. Glinskii
  • Patent number: 8293503
    Abstract: The invention provides vectors and methods for directional cloning.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: October 23, 2012
    Assignee: Promega Corporation
    Inventors: Michael R. Slater, Ethan Edward Strauss, Keith V. Wood, James Robert Hartnett
  • Patent number: 8241887
    Abstract: A bacterial growth medium for promoting auto-induction of transcription of cloned DNA in cultures of bacterial cells grown batchwise is disclosed. The transcription is under the control of a lac repressor. Also disclosed is a bacterial growth medium for improving the production of a selenomethionine-containing protein or polypeptide in a bacterial cell, the protein or polypeptide being produced by recombinant DNA techniques from a lac or T7lac promoter, the bacterial cell encoding a vitamin B12-dependent homocysteine methylase. Finally, disclosed is a bacterial growth medium for suppressing auto-induction of expression in cultures of bacterial cells grown batchwise, said transcription being under the control of lac repressor.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: August 14, 2012
    Assignee: Brookhaven Science Associates, LLC
    Inventor: F. William Studier
  • Patent number: 8216804
    Abstract: The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetases that can incorporate unnatural amino acids into proteins produced in eubacterial host cells such as E. coli, or in a eukaryotic host such as a yeast cell. The invention provides, for example but not limited to, novel orthogonal synthetases, methods for identifying and making the novel synthetases, methods for producing proteins containing unnatural amino acids, and translation systems.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: July 10, 2012
    Assignee: The Scripps Research Institute
    Inventors: Peter G. Schultz, Jianming Xie, Huaqiang Zeng
  • Patent number: 8211667
    Abstract: The present invention relates to isolated fungal promoter DNA sequences, to DNA constructs, vectors, and fungal host cells comprising these promoters in operative association with coding sequences encoding polypeptides. The present invention also relates to methods for expressing a gene and/or producing a polypeptide using the new promoters isolated. The present invention also relates to methods for altering the transcription level and/or regulation of an endogenous gene using the new promoter of the invention.
    Type: Grant
    Filed: April 18, 2005
    Date of Patent: July 3, 2012
    Assignee: DSM IP Assets B.V.
    Inventors: Thibaut José Wenzel, Noël Nicolaas Maria Elisabeth Van Peij, Hein Stam
  • Patent number: 8206898
    Abstract: The invention provides a target and methods for specific binding and inhibition of RNAP from bacterial species. The invention is directed to a method for identifying agents that bind to a bacterial RNAP homologous RNA-exit-channel amino-acid sequence, comprising preparing a reaction solution comprising the agent to be tested and an entity comprising a bacterial RNAP homologous RNA-exit-channel amino-acid sequence, and detecting presence or amount of binding. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: June 26, 2012
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Richard H. Ebright
  • Patent number: 8206968
    Abstract: The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: June 26, 2012
    Assignee: Yale University
    Inventors: Jennifer A. Doudna, Louise J. Lucast, Robert T. Batey
  • Patent number: 8206977
    Abstract: A tricistronic vector (i.e., a vector capable of expressing three exogenous genes, which are not fused together, under the control of one promoter) effectively can encode an immunoglobulin-presenting polypeptide and two immunoglobulin (Ig) polypeptides. The encoded Ig-presenting polypeptide is able to associate with at least one of the Ig polypeptides via co-expressed associating agents. A vector according to the present invention particularly is suited for phage display technology, e.g., when the Ig-presenting polypeptide is a phage coat protein and the Ig polypeptides associate to form a Fab.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: June 26, 2012
    Assignee: MorphoSys AG
    Inventors: Josef Prassler, Yvonne Stark
  • Patent number: 8183011
    Abstract: The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds/agents capable of modulating mRNA interferase activity and methods for using such compounds/agents. Also provided is a kit comprising mRNA interferase nucleic and/or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: May 22, 2012
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Masayori Inouye, Junjie Zhang, Yong Long Zhang
  • Patent number: 8168768
    Abstract: The present invention relates to methods for monitoring differential expression of a plurality of genes in a first filamentous fungal cell relative to expression of the same genes in one or more second filamentous fungal cells using microarrays containing Trichoderma reesei ESTs or SSH clones, or a combination thereof. The present invention also relates to computer readable media and substrates containing such array features for monitoring expression of a plurality of genes in filamentous fungal cells.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: May 1, 2012
    Assignee: Novozymes, Inc.
    Inventors: Randy Berka, Elena Bachkirova, Michael Rey
  • Patent number: 8168434
    Abstract: The present invention is related to a new method for replacing or deleting DNA sequences in Clostridia, with high efficiency, easy to perform and applicable at an industrial level. This method is useful to modify several genetic loci in Clostridia in a routine manner. This method is based on a replicative vector carrying at least two marker genes.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: May 1, 2012
    Assignee: Metabolic Explorer
    Inventors: Philippe Soucaille, Rainer Figge, Christian Croux
  • Patent number: 8158384
    Abstract: The present invention provides methods to reduce or eliminate ?-mannosidase resistant glycans on glycoproteins in yeast. The reduction or elimination of ?-mannosidase resistant glycans on glycoproteins results from the disruption of the newly isolated P. pastoris AMR2 gene encoding ?1,2-mannosyltransferase. The present invention also discloses novel genes, polypeptides, antibodies, vectors and host cells relating to ?-mannosidase resistance on glycans.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: April 17, 2012
    Assignee: Glycofi, Inc.
    Inventor: Piotr Bobrowicz
  • Patent number: 8158387
    Abstract: The present invention relates to an expression vector which can effectively express target proteins or peptides on the surface of cells using an outer membrane protein (FadL) of E. coli as a surface anchoring motif. Also, the present invention relates to microorganisms transformed with the expression vector, and a method for stably expressing large amounts of target proteins on the surface of cells by culturing the transformed microorganisms. Furthermore, the present invention relates to a production method of protein arrays, a production method of antibodies, and a bioconversion method, the methods being characterized by using target proteins which have been expressed on the cell surface by the inventive method. In addition, the present invention relates to a method for improving target proteins by the inventive surface expression method. The present invention allows target proteins with normal functions to be expressed on an outer cell membrane.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: April 17, 2012
    Assignee: Korea Advanced Institute of Science and Technology
    Inventors: Sang Yup Lee, Seung Hwan Lee, Si Jae Park
  • Patent number: 8153402
    Abstract: An emulsion is useful in allowing a wide variety of gene products to be expressed via eukaryotic in vitro expression. The emulsion comprises a silicone based surfactant, a hydrophobic phase and a hydrophilic phase; wherein the hydrophilic phase comprises a plurality of compartments containing a functional in vitro eukaryotic expression system.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: April 10, 2012
    Assignee: Medical Research Council
    Inventors: Phillip Holliger, Farid Ghadessy
  • Patent number: 8129166
    Abstract: The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: March 6, 2012
    Assignee: Vaxiion Therapeutics, Inc.
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark Surber
  • Patent number: 8119365
    Abstract: A bacteria lacking genomic and non-genomic IS elements is provided. The bacteria may be more stable and useful for the production of amino acids, polypeptides, nucleic acids and other products.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: February 21, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Frederick R. Blattner, John W. Campbell, David Frisch, Guy Plunkett, Gyorgy Posfai
  • Patent number: 8097454
    Abstract: A model system for screening and identification of compounds that interfere with Gli2 dependent tumorigenesis and provide potential use as anticancer agents is provided. In particular, the invention includes a Gli2 protein having an S662A point mutation that interferes with binding by the ubiquitin-ligase ?-TrCP. The mutation inhibits Gli2 degradation by the ubiquitin pathway. Gli2 stability and half-life are increased in the host cell resulting in an increase in Gli2-dependent transcription and concomitant neoplasia and tumorigenesis. Expression of the Gli2 mutant allows for the high throughput screening of compounds that interfere with the tumorigenesis thereby identifying anticancer agents.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: January 17, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Vladimir S. Spiegelman, Neehar Bhatia
  • Patent number: 8088620
    Abstract: The invention relates to optimised micro-organism strains for the biotransformation production of molecules having NADPH-consuming biosynthetic pathways. The inventive strains can be used in NADPH-consuming biotransformation methods. Said strains are characterized in that one or more NADPH-oxidizing activities are limited.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: January 3, 2012
    Assignee: Metabolic Explorer
    Inventors: Gwénaëlle Bestel-Corre, Cédric Boisart, Michel Chateau, Benjamin Gonzalez, Philippe Soucaille, Rainer Figge, Olivier Zink
  • Patent number: 8088623
    Abstract: The invention relates to a new expression vector for the transformation of eukaryotic cells, in particular fungal cells, or eukaryotic cell organelles as well as to a method for the transformation of eukaryotes, in particular fungi, or eukaryotic cell organelles employing these expression vector. The expression vector comprises at least one acc gene encoding at least one subunit of a MS-type acetyl-CoA carboxylase (MS-ACC), placed under the control of eukaryotic expression signals, and is a suitable selection marker for the transformation of eukaryotic cells, in particular fungal cells, or eukaryotic cell organelles to resistance to an inhibitor of MF-type acetyl-CoA carboxylases.
    Type: Grant
    Filed: February 9, 2004
    Date of Patent: January 3, 2012
    Inventors: Andreas Leclerque, Hong Wan
  • Patent number: 8088602
    Abstract: The present invention describes the use of thio-phosphate as a novel metabolite for chemically modifying mRNA in cells. Thio-phosphate is taken up by both prokaryotic and eukaryotic cells, incorporated into rNTP pools and ultimately mRNA. This enables the in vivo modification of mRNA with nuclease resistant phosphorothioate internucleotide linkages. Significant incorporation of thio-phosphate occurs such that RNA is significantly stabilized from degradation both in vivo and in vitro upon subsequent isolation. Thio-phosphate can be used as the sole source of phosphate in the culture medium for several generations resulting in a significant increase in the amount of mRNA per cell. The method should facilitate the detection and analysis of mRNA for research and diagnostic purposes. To enhance protein production it is necessary to use a mixture of thio-phosphate and phosphate in the culture medium.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: January 3, 2012
    Inventor: Elizabeth Gay Frayne